Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
Executive Summary
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs
You may also be interested in...
Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23
Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23
Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well
Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period